Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIONASDAQ:CLLSNASDAQ:CRBPNASDAQ:IFRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$3.70-0.3%$7.24$3.40▼$53.10$6.45M3.1294,584 shs16,951 shsCLLSCellectis$1.44-2.0%$1.47$1.10▼$2.43$81.71M2.93142,945 shs59,952 shsCRBPCorbus Pharmaceuticals$7.89-4.2%$7.58$4.64▼$61.90$100.83M3.12344,869 shs104,972 shsIFRXInflaRx$0.79-0.3%$1.26$0.71▼$2.82$53.38M1.29287,597 shs232,029 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics0.00%-8.62%-6.08%-71.38%-79.39%CLLSCellectis0.00%+10.53%0.00%+12.21%-22.22%CRBPCorbus Pharmaceuticals0.00%-6.68%+11.35%+38.26%-80.60%IFRXInflaRx0.00%+1.43%-57.02%-43.60%-48.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics2.5065 of 5 stars3.52.00.00.02.81.70.6CLLSCellectis2.8163 of 5 stars3.55.00.00.00.02.50.6CRBPCorbus Pharmaceuticals3.8598 of 5 stars3.61.00.04.71.12.50.6IFRXInflaRx2.7319 of 5 stars3.53.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,521.62% UpsideCLLSCellectis 3.00Buy$4.00177.78% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$50.88544.80% UpsideIFRXInflaRx 3.00Buy$6.60732.28% UpsideCurrent Analyst Ratings BreakdownLatest CDIO, CRBP, CLLS, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.005/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.003/26/2025IFRXInflaRxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K160.95N/AN/A$7.10 per share0.52CLLSCellectis$49.22M1.63N/AN/A$2.36 per share0.61CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AIFRXInflaRx$180K295.74N/AN/A$1.13 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/12/2025 (Estimated)CLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)CRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)IFRXInflaRx-$49.85M-$0.82N/AN/AN/A-33,362.70%-64.17%-53.39%8/6/2025 (Estimated)Latest CDIO, CRBP, CLLS, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A19.4719.47CLLSCellectis0.441.671.67CRBPCorbus PharmaceuticalsN/A11.8211.82IFRXInflaRxN/A5.284.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%CLLSCellectis63.90%CRBPCorbus Pharmaceuticals64.64%IFRXInflaRx42.39%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%CLLSCellectis16.41%CRBPCorbus Pharmaceuticals4.00%IFRXInflaRx16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableCLLSCellectis29055.58 million46.46 millionOptionableCRBPCorbus Pharmaceuticals4012.24 million11.75 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableCDIO, CRBP, CLLS, and IFRX HeadlinesRecent News About These CompaniesInflaRx N.V. (NASDAQ:IFRX) Sees Large Growth in Short InterestJune 19, 2025 | americanbankingnews.comInflaRx N.V. (NASDAQ:IFRX) Short Interest UpdateJune 18, 2025 | marketbeat.comBrokers Issue Forecasts for InflaRx FY2026 EarningsJune 10, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Sees Large Decline in Short InterestJune 4, 2025 | marketbeat.comInflaRx stock rating cut, price target slashed to $2 by Raymond JamesMay 30, 2025 | investing.comInflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | BenzingaMay 30, 2025 | benzinga.comOppenheimer Has Lowered Expectations for InflaRx (NASDAQ:IFRX) Stock PriceMay 30, 2025 | marketbeat.comInflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage UncertaintyMay 29, 2025 | tipranks.comInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | finanznachrichten.dePG rating: Inflarx review declares phase III bombMay 28, 2025 | bioworld.comInflaRx ditches vilobelimab Phase III trial in PGMay 28, 2025 | thepharmaletter.comInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28, 2025 | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28, 2025 | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28, 2025 | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpMay 28, 2025 | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28, 2025 | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, CRBP, CLLS, and IFRX Company DescriptionsCardio Diagnostics NASDAQ:CDIO$3.70 -0.01 (-0.27%) Closing price 04:00 PM EasternExtended Trading$3.69 -0.01 (-0.30%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Cellectis NASDAQ:CLLS$1.44 -0.03 (-2.04%) Closing price 03:58 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Corbus Pharmaceuticals NASDAQ:CRBP$7.89 -0.35 (-4.25%) Closing price 04:00 PM EasternExtended Trading$8.12 +0.24 (+2.98%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.InflaRx NASDAQ:IFRX$0.79 0.00 (-0.28%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.01 (+0.88%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
